Recursion Pharmaceuticals, Inc. (RXRX) Balance Sheet

The sequential decline in total assets, from $1.5B to $1.2B over two quarters, reflects a net cash outflow of roughly $200M, consistent with the prior income statement's operating losses. Equity also contracted from $1.1B to $915M, suggesting that the company is funding operations through existing cash rather than new equity issuance. This trajectory implies a weakening balance sheet unless the company secures additional financing or achieves a significant inflection in revenue.

The D/E ratio of 0.07 is low, but the absolute debt of $61.9M represents a meaningful claim on cash reserves of $545.7M. The reduction in debt from $108.5M to $61.9M suggests principal repayments, which may indicate a deliberate deleveraging strategy. However, with negative retained earnings and no clear path to profitability, the company's ability to refinance or service this debt without further dilution warrants monitoring.

The sharp increase in goodwill, from $52.1M in 2024Q3 to $160.3M in 2026Q2, suggests acquisition activity, likely the $277.1M outflow noted in the cash flow analysis. This raises the risk of future impairment if the acquired assets underperform. The declining PP&E indicates minimal capital investment, consistent with an asset-light model, but the growing intangibles may not provide collateral value, increasing balance sheet vulnerability.

The accumulated deficit has more than doubled over the ten-quarter period, reflecting persistent operating losses. Equity quality is low because it is primarily composed of paid-in capital rather than retained earnings, and the growing deficit suggests that future profitability is distant. The lack of share repurchases or dividends, as noted in the cash flow analysis, means shareholders are not receiving returns, and dilution from SBC is likely increasing share count, further eroding per-share value.

The current ratio of 5.03 suggests ample short-term liquidity, but the absolute cash decline of ~$200M over two quarters indicates a rapid consumption rate. Based on the prior cash flow analysis, operating cash burn averages around $100M per quarter, implying that the current cash position may only last about five quarters without additional financing. This liquidity buffer is adequate for the near term but may not be sufficient to reach profitability, especially if revenue growth does not materialize.

The decline in deferred revenue indicates that the company is recognizing revenue from existing collaborations faster than it is signing new ones, which may signal a slowdown in partnership activity. This is consistent with the volatile revenue pattern observed in the income statement, where collaboration payments are lumpy. The decreasing deferred revenue balance implies that future revenue visibility is limited, and the company may need to secure new partnerships to sustain its operations.